B&K Corporation Limited (HKG: 2396) officially listed on the Hong Kong Stock Exchange today, offering 17,648,800 shares at a maximum price of HK$51 per share, successfully raising over HK$900 million (≈ US$115 M). The biopharmaceutical company, founded in 2012, focuses on protein‑based therapies for unmet medical needs.
Advance Pro‑101 programs to Phase III; expand manufacturing; fund pipeline expansion
Company Overview
Founded
Focus
Technology
2012
Protein drugs for indications with unmet needs
Recombinant protein platform
Core Pipeline
Asset
Indication
Stage
Key Data
Pro‑101‑1
Deep second‑degree burns/scalds
Phase IIb complete
Statistical analysis finalized
Pro‑101‑1
Superficial second‑degree burns/scalds
Phase IIb complete
Last patient finished; data pending
Pro‑101‑2
Diabetic foot ulcers
Phase II ongoing
Enrollment continues
Other Candidates
Undisclosed indications
Discovery/pre‑clinical
8 additional assets
Market Opportunity
Indication
Target Market
Key Driver
Burns (China)
~ 1.5 million hospitalizations annually
Limited effective protein therapies; Pro‑101‑1 addresses wound healing
Diabetic Foot Ulcers
15‑25% of diabetic patients develop DFU
High unmet need for advanced wound‑healing agents
Peak Sales Forecast (Pro‑101‑1)
¥2‑3 billion (≈ US$280‑420 M) by 2033
Assumes 20‑25% share of severe burn segment post‑approval
Strategic Implications
Capital Infusion: HK$900 M raise extends runway through 2027, funding Pro‑101‑1 Phase III initiation and Pro‑101‑2 trial completion.
Platform Validation: Successful IPO demonstrates investor confidence in protein drug platform and late‑stage burn asset in a market lacking innovative treatments.
Pipeline Expansion: Proceeds will support advancement of 8 additional candidates, potentially broadening into regenerative medicine and chronic wound care.
Forward‑Looking Statements This brief contains forward‑looking statements regarding B&K’s use of IPO proceeds, clinical timelines, and market penetration for Pro‑101 programs. Actual results may differ due to clinical risks, regulatory delays, or competitive responses.-Fineline Info & Tech
Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.
